Clinical significance of mutations (ESCAT)

Tumor-board context — the engine does not use these tiers to rank tracks

Biomarker	Variant	ESCAT	Evidence	Clinical significance	Drugs	Sources
No clinically actionable variants matched in this profile.

Primary current-line option

Standard plan

★ DEFAULT

Indication

IND-CHONDROSARCOMA-ADVANCED-DOXORUBICIN

Regimen

Doxorubicin monotherapy (advanced chondrosarcoma, 1L palliative)

Drugs + NSZU

Doxorubicin (DRUG-DOXORUBICIN) Doxorubicin 75 mg/m² IV q3w × 6 cycles (cumulative cap 450 mg/m²) · Per regimen schedule · IV ⚠ NSZU — not for this indication

Reason

Primary current-line option selected by ALGO-CHONDROSARCOMA-1L at the fallback path.

Timeline

Treatment timeline — derived from regimen + monitoring schedule

Standard plan

Induction · Doxorubicin monotherapy (advanced chondrosarcoma, 1L palliative)

21-day cycles × 6 cycles or until progression / toxicity

MDT brief

MDT talk tree (1 steps)

#	Owner	Topic	Action
1	palliative_care	Specialist review	Reduced performance status / decompensated comorbidity — goals-of-care assessment needed.

Skills (recommended) — for consideration (1)

Palliative care recommended
Reduced performance status / decompensated comorbidity — goals-of-care assessment needed.

Data quality

Usable with caveats. No critical default-track gap was found, but the MDT should review the listed caveats before final sign-off.

Biomarker coverage: 0/0 known (100%), 0 missing, 0 default-track gaps
Unevaluated RedFlags: RF-CHONDROSARCOMA-FRAILTY-AGE, RF-CHONDROSARCOMA-HIGH-RISK-BIOLOGY, RF-CHONDROSARCOMA-INFECTION-SCREENING, RF-CHONDROSARCOMA-ORGAN-DYSFUNCTION, RF-CHONDROSARCOMA-TRANSFORMATION-PROGRESSION

Technical MDT skill metadata (1/16 activated in this plan)

All registered virtual specialists. ✓ — activated for this case; ○ — not activated (available for other clinical scenarios).

Specialist	skill_id	Version	Last reviewed	Domain
Cellular therapy specialist (CAR-T)	`cellular_therapy_specialist`	v0.1.0	2026-04-25	cellular_therapy
Clinical pharmacist	`clinical_pharmacist`	v0.1.0	2026-04-25	clinical_pharmacy
Hematologist / oncohematologist	`hematologist`	v0.1.0	2026-04-25	hematology_oncology
Hematopathologist (lymphoma / leukemia / myeloma)	`hematopathologist`	v0.1.0	2026-04-25	hematopathology
Infectious disease / hepatology	`infectious_disease_hepatology`	v0.1.0	2026-04-25	infectious_diseases
Medical oncologist (solid-tumor chemotherapist)	`medical_oncologist`	v0.1.0	2026-04-25	solid_oncology
Molecular geneticist / molecular oncologist	`molecular_geneticist`	v0.1.0	2026-04-25	molecular_oncology
Palliative care	`palliative_care`	v0.1.0	2026-04-25	palliative_care
Pathologist (general)	`pathologist`	v0.1.0	2026-04-25	pathology
Primary care / family physician	`primary_care`	v0.1.0	2026-04-25	primary_care
Psycho-oncologist	`psychologist`	v0.1.0	2026-04-25	psychosocial
Radiation oncologist	`radiation_oncologist`	v0.1.0	2026-04-25	radiation_oncology
Radiologist	`radiologist`	v0.1.0	2026-04-25	diagnostic_imaging
Social worker / case manager	`social_worker_case_manager`	v0.1.0	2026-04-25	psychosocial
Surgical oncologist	`surgical_oncologist`	v0.1.0	2026-04-25	surgical_oncology
Transplant specialist (BMT)	`transplant_specialist`	v0.1.0	2026-04-25	cellular_therapy

Sources cited

SRC-NCCN-SARCOMA: NCCN Soft Tissue Sarcoma guideline (TODO: confirm year/citation) ()

Experimental options (clinical trials)

Third plan track — open-enrollment trials from ClinicalTrials.gov. Render-time metadata; engine selection is not affected by this block (CHARTER §8.3). Last synced: 2026-05-13.

NCT	Title	Phase	Status	Sponsor	UA	Signals
NCT06176989	Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors	PHASE2	RECRUITING	National Cancer Institute (NCI)	—	Small N (<50) Surrogate endpoint only Single country
NCT03442465	Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas	N/A	RECRUITING	Memorial Sloan Kettering Cancer Center	—	Single country
NCT05039801	IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors	PHASE1	RECRUITING	M.D. Anderson Cancer Center	—	Phase 1 only Single country
NCT07315542	Diagnostic and Therapeutic Targets in Cartilaginous Tumours	N/A	RECRUITING	St. Anne's University Hospital Brno, Czech Republic	—	Single country
NCT04673942	A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors	PHASE2	RECRUITING	EpicentRx, Inc.	—	Single country
NCT05861245	Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base	NA	RECRUITING	Quironsalud	—	Small N (<50) Single country
NCT04087902	Long-Term Longitudinal QoL in Patients Undergoing EEA	N/A	RECRUITING	Ohio State University	—	Single country
NCT05033288	Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone	N/A	RECRUITING	Mayo Clinic	—	Single country
NCT04040205	Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration	PHASE2	RECRUITING	Medical College of Wisconsin	—	Small N (<50) Surrogate endpoint only Single country
NCT06387485	A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative Planning	NA	RECRUITING	Ricoh USA, Inc.	—	Single country

Verify recruitment status directly with the trial site. ctgov data can lag behind current UA-site status.

Option availability in Ukraine

Per-track UA registration · NSZU · cost · access pathway. Render-time metadata; engine selection does not depend on these fields (CHARTER §8.3).

Option	UA registration	NSZU	Cost orientation	Access pathway
Standard plan Doxorubicin monotherapy (advanced chondrosarcoma, 1L palliative) (REG-DOXORUBICIN-CHONDROSARCOMA)	✓ registered	✓ covered	₴-? — verify pathway	NSZU formulary
Trial · NCT06176989 Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT03442465 Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT05039801 IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT07315542 Diagnostic and Therapeutic Targets in Cartilaginous Tumours No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT04673942 A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT05861245 Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT04087902 Long-Term Longitudinal QoL in Patients Undergoing EEA No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT05033288 Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT04040205 Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT06387485 A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative Planning No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor

Cost information is orientation. Verify with a specific pharmacy / foundation / trial site. Status updated: 2026-05-13.

plan_id: PLAN-VAR-CHONDROSARCOMA-FRAIL-V1 | version: 1 | generated: 2026-05-13T10:01:51.821569+00:00

Per FDA non-device CDS positioning (CHARTER §15): Outpatient oncology treatment planning to support tumor-board discussion. Not a medical device; not for autonomous clinical decision-making.

Per FDA non-device CDS positioning (CHARTER §15): Both treatment options below are presented for review. The engine's selection of a 'recommended' default does not constitute a clinical decision. Final treatment selection requires HCP judgment incorporating information not available to the system.

This document is an informational resource supporting tumor-board discussion (per CHARTER §11). It is not a system that makes clinical decisions. Every recommendation must be verified by the treating physician.